Skip to main content

Improved Cardiac Function From Gene Therapy

Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population. The data are published online in the June 27 issue of the American Heart Association journal Circulation.

SERCA2a is delivered via an adeno-associated virus vector -- an inactive virus that acts as a medication transporter -- into cardiac cells. The therapy stimulates production of an enzyme within these cells that enables the heart to pump more effectively in people with advanced heart failure. After one year, patients who were administered a high dose SERCA2a demonstrated improvement or stabilization. Gene therapy with SERCA2a was also found to be safe in this sick patient population, with no increases in adverse events, disease-related events, laboratory abnormalities, or arrhythmias compared to placebo.

"Few treatment options have shown such improved clinical outcomes in this patient population in the last decade," said Roger J. Hajjar, MD, Research Director of Mount Sinai's Wiener Family Cardiovascular Research Laboratories, and the Arthur and Janet C. Ross Professor of Medicine, and Gene and Cell Medicine, Mount Sinai School of Medicine. "This study establishes a new paradigm for the treatment of heart failure by clinically validating SERCA2a as a novel target. In addition, by showing that adeno-associated vectors are safe to use in patients with advanced heart failure, this study ushers a new era for gene therapy for the treatment of failing hearts."

The CUPID (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) trial is a randomized, double-blind, placebo-controlled study, which enrolled 39 patients with advanced heart failure to study the safety and efficacy of SERCA2a. Patients were randomized to receive SERCA2a gene delivery in one of three doses or placebo, and were evaluated over one year. The treatment is delivered directly to the patient's heart during a routine outpatient cardiac catheterization procedure.

Patients in the high-dose SERCA2a group demonstrated improvement and/or stabilization in symptoms, overall heart function, biomarker activity, and ventricular mechanics and function. They also saw a dramatic reduction in cardiovascular hospitalizations, averaging 0.4 days versus 4.5 days in the placebo group.

"Even though heart failure mortality has decreased over the last decade with the help of standard pharmacological and device therapies, patients with advanced heart failure continue to die at high rates. The CUPID trial offers a new therapeutic option for these patients," said Dr. Hajjar.

Led by Dr. Hajjar, the Mount Sinai team discovered the landmark potential of the cardiac-specific target in 1999 and has been pursuing its potential as a treatment delivered via gene therapy in state-of-the-art custom built laboratories at Mount Sinai School of Medicine in New York.

According to the U.S. Centers for Disease Control and Prevention, about 5.8 million Americans suffer from heart failure, and 670,000 new cases are diagnosed each year. One in five people who have heart failure die within one year of diagnosis. In 2010, heart failure will cost the United States $39.2 billion, including the cost of health care services, medications, and lost productivity. Heart failure is most often treated with aggressive medical and device therapy, but has no cure. The most common symptoms of heart failure are shortness of breath, feeling tired, and swelling in the ankles, feet, legs, and sometimes the abdomen.

The CUPID Trial is funded by Celladon Corporation. The company was co-founded by Dr. Hajjar who has an equity interest in Celladon Corporation and participates on an Advisory Board.

Source: The Mount Sinai Hospital / Mount Sinai School of Medicine, via EurekAlert.

Comments

Popular posts from this blog

Charging Implanted Heart Pumps Wirelessly

Mechanical pumps to give failing hearts a boost were originally developed as temporary measures for patients awaiting a heart transplant. But as the technology has improved, these ventricular assist devices commonly operate in patients for years, including in former vice-president Dick Cheney, whose implant this month celebrates its one-year anniversary. Prolonged use, however, has its own problems. The power cord that protrudes through the patient's belly is cumbersome and prone to infection over time. Infections occur in close to 40 percent of patients, are the leading cause of rehospitalization, and can be fatal. Researchers at the University of Washington and the University of Pittsburgh Medical Center have tested a wireless power system for ventricular assist devices. They recently presented the work in Washington, D.C. at the American Society for Artificial Internal Organs annual meeting, where it received the Willem Kolff/Donald B. Olsen Award for most promising research in

Autism and Eye Contact: Genes very much are involved

We have now a lot of evidence on genetic components in many disorders including neurological in both adults and kids. Autism is one such problem that has many genes involved. Research is still in full swing to find more genes and related pathways. However, one can find autistic features more phenotypically before genotyping. Eye contact is one of them. Studies have shown that autistic kids make less eye contact. This has been shown to have genetic component now. New research has uncovered compelling evidence that genetics plays a major role in how children look at the world and whether they have a preference for gazing at people's eyes and faces or at objects. The discovery by researchers at Washington University School of Medicine in St. Louis and Emory University School of Medicine in Atlanta adds new detail to understanding the causes of autism spectrum disorder. The results show that the moment-to-moment movements of children's eyes as they seek visual information about the

How much people depend on weather reports

Meteorologists on television, radio, online, and in newspapers supply weather reports to the average person over 100 times a month. Surveys demonstrated that the 300 billion forecasts accessed generate a value of $285 per household every year, or $32 billion for the entire United States. Odds are you have already watched one weather forecast today and will probably check out a few more. Accurate, timely forecasts are vital to everyday life, but just how critical may surprise you. Whether at work or play, you probably watch the weather quite closely. Most of us are at the weather person's mercy to know what to wear, what to expect, to prepare for the worst. New research shows the average United States household checks out a weather report more than three times a day. "It impacts pretty much every part of every activity we are involved with for the most part," Jeff Lazo, the director of the Societal Impacts Program at the National Center for Atmospheric Research (NCAR) in B